GlassScriptPhysician profile
Sean Delair
NPI 1730155094
$4,384.85
in general payments reported to CMS, 2019-2025
34 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $411 · 2021: $362 · 2022: $356 · 2023: $472 · 2024: $698 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507 · Education: $8.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.56 |
| Education | $8.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $702.71 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, General - Erectile Dysfunction, Ams 700 |
| Neotract INC. | $597.93 | 2019-2020 | |
| Teleflex LLC | $358.44 | 2021-2025 | Urolift, Barrigel |
| C. R. Bard, INC. & Subsidiaries | $304.63 | 2022-2025 | Bard Urinary Drainage Bag, Magic3 Go Intermittent Urinary Catheter |
| Sumitomo Pharma America, INC. | $292.36 | 2023-2025 | Gemtesa |
| Urogen Pharma, INC. | $289.25 | 2021-2025 | |
| Procept Biorobotics Corporation | $245.21 | 2024-2025 | Aquabeam System |
| Medtronic, INC. | $235.50 | 2021-2024 | Interstim |
| Amgen INC. | $223.43 | 2019-2021 | |
| Caldera Medical, INC | $126.99 | 2022 | |
| Urovant Sciences INC | $101.32 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $100.74 | 2023-2025 | Prolaris |
| Coloplast Corp | $84.66 | 2019-2025 | |
| Tolmar, INC. | $80.81 | 2024-2025 | Jatenzo, Eligard |
| Rochester Medical Corporation | $59.10 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $57.49 | 2021-2024 | Bulkamid, Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $46.04 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $43.03 | 2022-2023 | Seglentis |
| Calyxo, INC. | $42.66 | 2025 | Cvac Aspiration System |
| Medtronic USA, INC. | $42.30 | 2019-2020 | |
| Ambu INC. | $41.81 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.96 | 2021-2025 | Lifevest |
| Acera Surgical, INC. | $35.01 | 2025 | Restrata Wound Matrix |
| Astellas Pharma US INC | $33.17 | 2019-2020 | |
| Blue Earth Diagnostics | $26.61 | 2022 | |
| Telix Pharmaceuticals | $24.10 | 2024 | Illuccix |
| Radius Health, INC. | $22.66 | 2023 | Tymlos |
| Phathom Pharmaceuticals, INC. | $22.43 | 2025 | Voquezna |
| Pfizer INC. | $21.94 | 2024 | |
| Laborie Medical Technologies Corp. | $21.86 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Solventum Corporation | $17.28 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C.Ulta |
| Corcept Therapeutics | $16.98 | 2025 | Korlym |
| Abbvie INC. | $14.67 | 2020 | |
| Olympus America INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Delair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.